MOG and neoplasm: Choe et al. recently reported engineered T lymphocytes that can conditionally express EphA2 and IL13Rα2-directed CAR under the control of a synNotch receptor recognizing both a tumor-specific but heterogeneous antigen (EGFRvIII) or an organ-specific antigen (myelin oligodendrocyte glycoprotein, or MOG) [137].